Holen Sie sich die Stockscreener-App
12.69
2.23%
-0.29
Handel nachbörslich:
12.69
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares - MarketBeat
Understanding the Setup: (TRDA) and Scalable Risk - Stock Traders Daily
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year HighTime to Buy? - MarketBeat
Aug Breakouts: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Gainers & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Volume: How does Entrada Therapeutics Inc compare to its peersJuly 2025 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Royce & Associates LP Raises Stock Position in Entrada Therapeutics, Inc. $TRDA - MarketBeat
HC Wainwright Has Optimistic Outlook of TRDA Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for TRDA Earnings - MarketBeat
Form 144: TRDA insider sales — Kory Wentworth sold 8,651 shares (TRDA) - Stock Titan
TRDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales - Stock Titan
Entrada Therapeutics (TRDA) CFO receives new equity grants and automatic tax share sales - Stock Titan
Entrada Therapeutics (TRDA) COO logs new RSU, option grants and tax share disposals - Stock Titan
Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes - Stock Titan
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants - National Today
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
The Technical Signals Behind (TRDA) That Institutions Follow - Stock Traders Daily
Entrada Therapeutics (TRDA) Quarterly Revenue Slump Tests Bullish Growth Narratives - simplywall.st
Entrada Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
TRDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) Posts Earnings Results, Beats Estimates By $0.38 EPS - MarketBeat
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 54% Potential Upside - DirectorsTalk Interviews
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TRDAForm S-8Securities to be offered to employees in employee benefit plans - ADVFN Ltd
Entrada Therapeutics Q4 net loss and EPS beat expectations - TradingView
Earnings Summary: Entrada Therapeutics Q4 - Benzinga
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Entrada Therapeutics (NASDAQ: TRDA) maps DMD, DM1 and ocular drug pipeline - Stock Titan
Entrada Therapeutics (TRDA) swings to 2025 loss while advancing DMD pipeline - Stock Titan
DMD trials advance as Entrada extends cash runway to Q3 2027 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
What analysts say about Entrada Therapeutics Inc. stockM&A Rumor & Long-Term Safe Investment Plans - mfd.ru
Entrada Therapeutics’ (TRDA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Potential Upside of 67.57% Could Attract Investors - DirectorsTalk Interviews
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline - Finviz
Entrada Therapeutics (TRDA) to Release Earnings on Thursday - Defense World
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains? - Yahoo Finance
HC Wainwright & Co. Reiterates Buy Rating on TRDA with $20 PT | - GuruFocus
Market Pulse: Should I trade or invest in Century Therapeutics IncJuly 2025 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - Bitget
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study - The Manila Times
Duchenne drug trial doubles dose to 12 mg/kg, aims at accelerated FDA approval - Stock Titan
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit - Defense World
Precision Trading with Entrada Therapeutics Inc. (TRDA) Risk Zones - Stock Traders Daily
What are Entrada Therapeutics Inc.’s recent SEC filings showingLayoff News & AI Driven Stock Price Forecasts - mfd.ru
Why analysts remain bullish on Entrada Therapeutics Inc. stockBear Alert & Reliable Price Breakout Alerts - mfd.ru
Will Entrada Therapeutics Inc. stock gain from lower inflationJuly 2025 Patterns & Long-Term Capital Growth Ideas - mfd.ru
Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim - MarketBeat
Published on: 2026-02-13 04:19:34 - mfd.ru
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):